Literature DB >> 5654059

Comparison of RNA terminal sequences of phages f2 and Q-beta: chemical and sedimentation equilibrium studies.

H L Weith, G T Asteriadis, P T Gilham.   

Abstract

The terminal fragment obtained by hydrolysis with ribonuclease T(1) of the ribonucleic acid from the bacteriophage Qbeta has been isolated and purified. The results of chemical and enzymatic hydrolysis of this fragment and of the intact RNA itself indicate that the fragment has the composition (10 Cp, 4 Up), and that the RNA has the terminal sequence -GP(9 Cp, 4 Up) CpA. These conclusions are supported by the results of an application of the sedimentation-equilibrium method in which the molecular weight of the Qbeta fragment was compared with that of the corresponding fragment from f2 phage RNA for which the terminal sequence, -GpUpUpApCpCpApCpCpCpA had previously been determined.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5654059     DOI: 10.1126/science.160.3835.1459

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  4 in total

1.  The in vitro addition of a polyadenylate sequence to the 3' end of phage Qbeta RNA and the biological activity of the product.

Authors:  C Gilvarg; F J Bollum; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

2.  The nucleotide sequence at the 5'-terminus of the Q RNA minus trand.

Authors:  H M Goodman; M A Billeter; J Hindley; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1970-10       Impact factor: 11.205

3.  Site-directed mutagenesis: effect of an extracistronic mutation on the in vitro propagation of bacteriophage Qbeta RNA.

Authors:  R A Flavell; D L Sabo; E F Bandle; C Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

4.  Characterization of the subunit structure of the ribonucleic acid genome of influenza virus.

Authors:  L J Lewandowski; J Content; S H Leppla
Journal:  J Virol       Date:  1971-11       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.